Regeneron Pharmaceuticals Inc (REGN) : Live Your Vision has sold out all of its stake in Regeneron Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Apr 11, 2016 with the SEC. The investment management company has sold out 390 shares of Regeneron Pharmaceuticals Inc which is valued at $158,625.
Regeneron Pharmaceuticals Inc closed down -0.1 points or -0.02% at $406.73 with 4,70,069 shares getting traded on Friday. Post opening the session at $408.86, the shares hit an intraday low of $400.89 and an intraday high of $409.7699 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Newman Dignan Sheerar sold out all of its stake in REGN during the most recent quarter. The investment firm sold 411 shares of REGN which is valued $167,166.Eqis Capital Management reduced its stake in REGN by selling 674 shares or 13.39% in the most recent quarter. The Hedge Fund company now holds 4,358 shares of REGN which is valued at $1,726,378. Regeneron Pharmaceuticals Inc makes up approx 0.12% of Eqis Capital Management’s portfolio.Creative Planning boosted its stake in REGN in the latest quarter, The investment management firm added 7,992 additional shares and now holds a total of 10,599 shares of Regeneron Pharmaceuticals Inc which is valued at $4,198,688. Regeneron Pharmaceuticals Inc makes up approx 0.03% of Creative Planning’s portfolio. New England Research Management added REGN to its portfolio by purchasing 975 company shares during the most recent quarter which is valued at $386,237. Regeneron Pharmaceuticals Inc makes up approx 0.33% of New England Research Management’s portfolio.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.50 based on the information available during the earnings call on Feb 9, 2016. Analyst had a consensus of $3.33. The company had revenue of $1098.00 million for the quarter, compared to analysts expectations of $1171.42 million. The company’s revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.79 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .Gabelli & Co Initiated Regeneron Pharmaceuticals Inc on Mar 15, 2016 to “Buy”, Price Target of the shares are set at $574.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.